Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Chan

Showing results (351-360 of 407) with videos related to

Pageof 41
Sort By:
Plos One|August 21, 2008
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivationYan Cui, Ying Ying, Andrew van Hasselt, et al.
Investigational New Drugs|June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)B B Y Ma, B C Goh, W T Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patientsMichael K M Kam, Sing-Fai Leung, Benny Zee, et al.
International Journal of Cancer|November 13, 2008
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistanceNathalie Wong, Winnie Yeo, Wai-Lap Wong, et al.
British Journal of Cancer|March 3, 2011
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patientsS C C Wong, S S M Ng, M T Cheung, et al.
Asia-Pacific Journal of Clinical Oncology|April 14, 2015
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancerBrigette B Ma, Frankie Mo, Joanna H Tong, et al.
Cancer|December 23, 2014
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinomaAnne W M Lee, Roger K C Ngan, Stewart Y Tung, et al.
Cancer|June 5, 2020
NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinomaAnne W M Lee, Roger K C Ngan, Wai-Tong Ng, et al.
Clinical Chemistry|October 26, 2005
Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinomaK C Allen Chan, Anthony T C Chan, Sing-Fai Leung, et al.
Oncogene|May 13, 2008
Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomasK Y Lee, H Geng, K M Ng, et al.
Pageof 41

Showing results (351-360 of 407) with videos related to

Sort By:
Pageof 41
Plos One|August 21, 2008
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivationYan Cui, Ying Ying, Andrew van Hasselt, et al.
Investigational New Drugs|June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)B B Y Ma, B C Goh, W T Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patientsMichael K M Kam, Sing-Fai Leung, Benny Zee, et al.
International Journal of Cancer|November 13, 2008
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistanceNathalie Wong, Winnie Yeo, Wai-Lap Wong, et al.
British Journal of Cancer|March 3, 2011
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patientsS C C Wong, S S M Ng, M T Cheung, et al.
Asia-Pacific Journal of Clinical Oncology|April 14, 2015
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancerBrigette B Ma, Frankie Mo, Joanna H Tong, et al.
Cancer|December 23, 2014
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinomaAnne W M Lee, Roger K C Ngan, Stewart Y Tung, et al.
Cancer|June 5, 2020
NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinomaAnne W M Lee, Roger K C Ngan, Wai-Tong Ng, et al.
Clinical Chemistry|October 26, 2005
Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinomaK C Allen Chan, Anthony T C Chan, Sing-Fai Leung, et al.
Oncogene|May 13, 2008
Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomasK Y Lee, H Geng, K M Ng, et al.
Pageof 41